An Oral Nanozyme Microsupplement Converts Pathological ROS Into a Colon‐Adhesive Shield for Long‐Term Neutrophil‐Directed Remission of Ulcerative Colitis
Advanced Materials · 2026
DOI: 10.1002/adma.75234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Xinying Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Macau, Macau SAR, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Reactive Oxygen Species, Neutrophils, Colon. Die Arbeit nennt 72 Literaturangaben. Gefördert von: National Natural Science Foundation of China, University of Macau and the University of Macau Development Foundation (UMDF), Science and Technology Development Fund, Macau SAR.
Abstract (Originalsprache)
Neutrophil extracellular traps (NETs) perpetuate chronic inflammation in ulcerative colitis (UC), yet current neutrophil‐targeting therapies focus on acute intervention rather than sustained daily control. Here, we propose an oral microsupplement for long‐term UC management that concurrently scavenges reactive oxygen species (ROS) and suppresses NET formation. The microsupplement integrates a catalase‐mimetic CoAl‐layered double hydroxide (LDH) nanozyme intercalated with the autophagy inhibitor chloroquine (CQ), together with dopamine (DOPA). The LDH nanozyme catalytically converts pathological ROS into oxygen, driving in situ polymerization of DOPA into polydopamine (PDA), a mucoadhesive polymer that prolongs colonic retention of CQ@LDH and promotes mucosal healing. RNA sequencing reveals that internalized CQ@LDH inhibits autophagic flux in neutrophils, thereby upregulating catalase expression and peroxisomal function to prevent NET formation. Consequently, NET‐driven M1 macrophage polarization is reduced from 29.5% to 17.9%, and Th17 differentiation is markedly suppressed, accompanied by a decrease in colonic Th17/Treg ratio from 8.68 to 1.31. In a murine UC model, this microsupplement restores colonic mucosal integrity, rebalances the gut microbiota, and outperforms the clinical drug 5‐aminosalicylic acid in both immune regulation and epithelial restitution. This neutrophil‐regulating, colon‐adhesive platform offers a promising strategy for routine daily UC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Macau, Macau SAR, China.
- MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, China.
ORCID-Profile: Ziliang Yan, Kai Luo, Meifang Wang, Bei Li, Yunlu Dai
Förderung
- National Natural Science Foundation of China
- University of Macau and the University of Macau Development Foundation (UMDF)
- Science and Technology Development Fund, Macau SAR
- Guangdong Provincial Applied Science and Technology Research and Development Program
- International Science &Technology Cooperation Program of Hainan Province
Zitieren
APA
Yu, X., Yu, X., Yan, Z., Tan, Y., Li, S., Feng, Y., Luo, K., Wang, M., Zhu, X., Li, B., & Dai, Y. (2026). An Oral Nanozyme Microsupplement Converts Pathological ROS Into a Colon‐Adhesive Shield for Long‐Term Neutrophil‐Directed Remission of Ulcerative Colitis. Advanced Materials. https://doi.org/10.1002/adma.75234
Vancouver
Yu X, Yu X, Yan Z, Tan Y, Li S, Feng Y, et al. An Oral Nanozyme Microsupplement Converts Pathological ROS Into a Colon‐Adhesive Shield for Long‐Term Neutrophil‐Directed Remission of Ulcerative Colitis. Advanced Materials. 2026. doi:10.1002/adma.75234
BibTeX
@article{Yu2026,
author = {Yu, Xinying and Yu, Xinwang and Yan, Ziliang and Tan, Yan and Li, Songhao and Feng, Yuzhao and Luo, Kai and Wang, Meifang and Zhu, Xiaoling and Li, Bei and Dai, Yunlu},
title = {An Oral Nanozyme Microsupplement Converts Pathological ROS Into a Colon‐Adhesive Shield for Long‐Term Neutrophil‐Directed Remission of Ulcerative Colitis},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.75234}
}
EUVIMED